脑心共患疾病共治与分治模式的卫生经济学比较研究

doi:10.3969/j.issn.1673-5765.2024.08.002

摘要/Abstract

摘要：

目的评估脑心共患疾病在共治与分治两种模式下的卫生经济学效益，以确定更优的医疗策略，提高治疗效率与经济效益。

方法本研究采用回顾性分析方法，收集2019年1月—2023年12月在首都医科大学附属北京天坛医院心血管内科、神经内科、神经外科、心血管外科和介入放射科等治疗的，符合中国疾病诊断相关分组（Chinese diagnosis related groups，CN-DRG）中神经系统疾病及功能障碍合并循环系统疾病及功能障碍患者的病历资料，记录患者的人口学特征、总住院天数、各类医疗费用以及病例组合指数（case mix index，CMI）和权重（relative weight，RW）。将患者分为共治组（一次住院期间对患者的脑心共患疾病进行统筹规划和综合治疗）与分治组（不同住院期间分别进行神经系统和心血管系统疾病的治疗），比较两组的基线特点及总住院天数、费用等经济学指标。

结果共纳入442例患者数据。共治组总住院天数低于分治组（6 d vs. 14 d，P<0.001）。经济学效益分析显示，共治组住院总费用低于分治组（65 967元 vs. 106 673元，P<0.001）。此外，共治组的RW高于分治组（2.24 vs. 1.61，P<0.001）。

结论相较于分治模式，共治模式下脑心共患疾病患者的住院时间更短，住院费用更低。共治模式有利于优化脑心共患疾病的医疗资源配置和诊疗流程。

文章导读：

脑心共患疾病联合诊疗（共治）模式在资源利用和经济效益上具有潜在优势。这种模式有助于提高疾病诊疗的卫生经济学效益，减轻患者的疾病负担。

关键词: 脑心共患疾病; 共治; 卫生经济学; 资源配置; 诊疗流程

Abstract:

Objective To evaluate the health economic benefits of the co-management and separate management models for patients with brain-heart comorbidity diseases, to determine better medical strategy, and to improve treatment efficiency and financial benefits.

Methods This study used a retrospective analysis method to collect the medical records of patients who were clarified into both neurological disorders and dysfunction (code MDCB) and cardiovascular diseases (code MDCF) following the Chinese diagnosis related groups (CN-DRG) method, and received treatment at the department of cardiovascular, department of neurology, department of neurosurgery, department of cardiovascular surgery, and department of interventional radiology of Beijing Tiantan Hospital, Capital Medical University from January 2019 to December 2023. The data including demographic characteristics, total length of hospital stay, various medical expenses, case mix index (CMI), and relative weight (RW) were recorded. Patients were divided into two groups: a co-management group (comprehensive treatment of cerebrovascular and cardiovascular diseases during a single hospitalization) and a separate management group (treatment of neurological and cardiovascular diseases during separate hospitalizations). The baseline characteristics and economic indexes including the total length of hospital stay and medical expenses were compared between the two groups.

Results A total of 442 patient data were included. The total length of hospital stay in the
co-management group was significantly shorter than that in the separate management group (6 days vs. 14 days, P<0.001). The economic benefit analysis showed that the total cost in the co-management group was significantly lower than that in the separate management group
(¥65 967 vs. ¥106 673, P<0.001). In addition, the RW value in the co-management group was significantly higher than that in the separate management group (2.24 vs. 1.61, P<0.001).

Conclusions Compared with the separate management model, the co-management model provides shorter hospital stays and lower total costs for patients with brain-heart comorbidity diseases, which is of great significance for optimizing the allocation of medical resources and the patient’s diagnosis and treatment process.

Key words: Brain-heart comorbidity disease; Integrated treatment; Health economics; Resource allocation; Diagnostic and treatment process

中图分类号:

夏岩, 王晓岩, 林发, 梁艳超, 张佳妮.

脑心共患疾病共治与分治模式的卫生经济学比较研究 [J]. 中国卒中杂志, 2024, 19(8): 867-872.

XIA Yan, WANG Xiaoyan, LIN Fa, LIANG Yanchao, ZHANG Jiani.

A Comparative Study of Health Economics of Co-Management and Separate Management Models for Brain-Heart Comorbidity Diseases [J]. Chinese Journal of Stroke, 2024, 19(8): 867-872.

参考文献

[1] 赵继宗，郭彩霞. 破楚汉界，立新学科——谈谈“脑心同治”[J]. 中华医学杂志，2019，99（39）：3041-3042.

ZHAO J Z，GUO C X. Break the boundaries，establish new discipline：comprehensive treatment of cerebro-cardiac disease[J]. Natl Med J China，2019，99（39）：3041-3042.

[2] 夏岩，姜悦. 脑心共患疾病防治体系建设思路和构想[J]. 中华医学杂志，2019，99（39）：3043-3046.

XIA Y，JIANG Y. Thoughts and ideas on the establishment for simultaneous prevention and treatment of brain and heart diseases[J]. Natl Med J China，2019，99（39）：3043-3046.

[3] 谢依热·哈木拉提，赵倩，李丞，等. 基于真实世界的缺血性心脑血管共患疾病的临床特征及卫生经济学评价[J]. 上海交通大学学报（医学版），2022，42（6）：778-785.

HAMULATI X，ZHAO Q，LI C，et al. Clinical characteristics and health economics evaluation of real-world-based ischemic cardiovascular and cerebrovascular co-morbidities[J]. Journal of Shanghai Jiao Tong University（Medical Science），2022，42（6）：778-785.

[4] 赵继宗. 创建脑心同治新学科，迎接新时代的新挑战[EB/OL].（2023-06-24）[2024-04-01].
https://m.thepaper.cn/baijiahao_23613797.

ZHAO J Z. Creating a new discipline of cerebro-cardiac co-treatment to meet the new challenges of the era[EB/OL]. （2023-06-24）[2024-04-01].
https://m.thepaper.cn/baijiahao_23613797.

[5] 赵国光. 医患共同决策的研究现状及展望[J]. 中国医院管理，2020，40（1）：59-62.

ZHAO G G. Research situation and expectation of doctor-patient shared decision making[J]. Chinese Hospital Management，2020，40（1）：59-62.

[6] 丁欣. 心脑共患疾病的临床特征及卫生经济学评价[D]. 新疆：新疆医科大学，2021.

DING X. Study on clinical characteristics and health economics evaluation of heart and brain comorbidity[D]. Xinjiang：Xinjiang Medical University，2021.

[7] 郭志刚.“心脑共病”在心血管外科中的综合治疗策略[J]. 中国现代神经疾病杂志，2024，24（1）：5-7.

GUO Z G. Comprehensive treatment strategies of “cardio-brain comorbidity” in cardiovascular surgery[J]. Chin J Contemp Neurol Neurosurg，2024，24（1）：5-7.

[8] 杜乐勋，柴正言，张志军. 卫生技术经济讲座第五讲：成本效益分析与成本效果分析[J/OL]. 中国卫生经济，1987，（5）：52-56[2024-04-01]. http://doi.
org/CNKI：SUN：WEIJ.0.1987-05-020.

DU L X，CHAI Z Y，ZHANG Z J. Health technology economics lecture，lecture 5：cost-benefit analysis and cost-effectiveness analysis[J/OL]. Chinese Health Economics，1987，（5）：52-56[2024-04-01]. http://doi.org/CNKI：SUN：WEIJ.0.1987-05-020.

[9] CORTAREDONA S，VENTELOU B. The extra cost of comorbidity：multiple illnesses and the economic burden of non-communicable diseases[J/OL]. BMC Med，2017，15（1）：216[2024-04-09]. https://doi.org/10.1186/s12916-017-0978-2.

[10] KHUNTI K，SATHANAPALLY H，MOUNTAIN P. Multiple long term conditions，multimorbidity，and co-morbidities：we should reconsider the terminology we use[J/OL]. BMJ，2023，383：2327[2024-05-09]. https://doi.org/10.1136/bmj. p2327.

[11] 谭华珍，于磊，周爱莲，等. 按病种分值付费影响住院医保费用结算差额的因素分析[J]. 中国病案，2020，21（10）：58-62.

TAN H Z，YU L，ZHOU A L，et al. Analysis the influencing factors for the settlement balance of hospitalization insurance expenses under payment by disease score[J]. Chinese Medical Record，2020，21（10）：58-62.

[12] 贺哲，翁雨雄，夏家红，等. 基于DRG的临床医师医疗能力评价体系构建及应用[J]. 中国卫生质量管理，2022，29（10）：58-61.

HE Z，WENG Y X，XIA J H，et al. Construction and application of the evaluation system of physicians’ medical competence based on DRG[J]. Chinese Health Quality Management，2022，29（10）：58-61.

[13] BANERJEE A，PASEA L，CHUNG S C，et al. A population-based study of 92 clinically recognized risk factors for heart failure：co-occurrence，prognosis and preventive potential[J]，Eur J Heart Fail，2022，24（3）：466-480.

[14] NEUMANN P J，COHEN J T，WEINSTEIN M C. Updating cost-effectiveness-the curious resilience of the $50 000-per-QALY threshold[J]. N Engl J Med，2014，371（9）：796-797.

[15] ZAPKA J G，PALMER R H，HARGRAVES J L，et al. Relationships of patient satisfaction with experience of system performance and health status[J]. J Ambul Care Manag，1995，18（1）：73-83.

[16] GOETZ L H，SCHORK N J. Personalized medicine：motivation，challenges，and progress[J]. Fertil Steril，2018，109（6）：952-963.

[17] 赵继宗. 我国脑心血管共患疾病现状与临床研究[J]. 首都医科大学学报，2022，43（5）：671-673.

ZHAO J Z. Current status and clinical research of brain-heart comorbid vascular diseases in China[J]. Journal of Capital Medical University，2022，43（5）：671-673.